BioNTech (NASDAQ:BNTX) Sees Large Volume Increase

Shares of BioNTech SE (NASDAQ:BNTX) saw unusually-strong trading volume on Monday . Approximately 1,013,933 shares traded hands during trading, an increase of 46% from the previous session’s volume of 693,292 shares.The stock last traded at $99.73 and had previously closed at $89.94.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of recent research reports. Evercore ISI initiated coverage on BioNTech in a research note on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target for the company in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research note on Tuesday, August 27th. Finally, TD Cowen cut their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $109.09.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The company has a market cap of $23.60 billion, a price-to-earnings ratio of 201.26 and a beta of 0.23. The business has a fifty day moving average price of $85.52 and a 200 day moving average price of $89.30.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same period in the previous year, the firm posted ($0.86) EPS. The firm’s revenue was down 23.3% compared to the same quarter last year. As a group, research analysts anticipate that BioNTech SE will post -2.8 earnings per share for the current year.

Institutional Trading of BioNTech

A number of hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new stake in shares of BioNTech during the 2nd quarter valued at $223,000. Granite Bay Wealth Management LLC acquired a new position in shares of BioNTech in the second quarter valued at approximately $1,483,000. Scientech Research LLC bought a new position in BioNTech in the 2nd quarter valued at approximately $1,127,000. Deerfield Management Company L.P. Series C boosted its position in BioNTech by 4.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares during the period. Finally, Employees Retirement System of Texas grew its holdings in BioNTech by 15.7% during the 2nd quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock worth $2,442,000 after acquiring an additional 4,115 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.